Company Overview - Columbus Circle Capital Corp. I is a blank check company formed to effect mergers, amalgamations, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses [7] - The management team includes Gary Quin as CEO and Chairman, and Joseph W. Pooler, Jr. as CFO, along with independent directors Garrett Curran, Alberto Alsina Gonzalez, Dr. Adam Back, and Matthew Murphy [7] Initial Public Offering (IPO) Details - The company closed its upsized initial public offering of 25,000,000 units, with gross proceeds of $250,000,000, priced at $10.00 per unit [1] - The offering included 3,000,000 units from the partial exercise of the underwriters' overallotment option [1] - Units began trading on NASDAQ under the ticker symbol "CCCMU" on May 16, 2025, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant [2] Financial and Legal Aspects - The proceeds from the IPO and a simultaneous private placement were placed in the company's trust account for the benefit of public shareholders [6] - The registration statement for the offering was declared effective by the SEC on May 15, 2025 [4] - Legal counsel for the company included Ellenoff Grossman & Schole LLP and Ogier (Cayman) LLP, while Loeb & Loeb LLP served as legal counsel to the underwriters [3] Cohen & Company Overview - Cohen & Company Inc. is a financial services company specializing in capital markets and asset management services [8] - The company operates through segments including Capital Markets, Asset Management, and Principal Investing, with a focus on mergers and acquisitions, capital markets, and SPAC advisory services [8] - As of March 31, 2025, Cohen & Company had approximately $2.3 billion in assets under management, primarily in fixed income assets [9]

Hong Kong, May 16, 2025 (GLOBE NEWSWIRE) -- MasterBeef Group (the “Company”), a full-service restaurant group in Hong Kong, specializing in Taiwanese hotpot and Taiwanese barbecue, today announced today that it has issued an additional 155,000 ordinary shares (the "Ordinary Shares") at a price of US$4.00 per share for gross proceeds of approximately $620,000, before deducting underwriter discounts and other related expenses, pursuant to the partial exercise of the underwriter's over-allotment option in conn ...

Group 1 - The Company, Columbus Circle Capital Corp I, has announced the pricing of its upsized initial public offering (IPO) of 22,000,000 units at a price of $10.00 per unit, with trading expected to begin on May 16, 2025 [1] - Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant allowing the purchase of one Class A ordinary share at a price of $11.50 per share [1] - The Company has granted underwriters a 45-day option to purchase an additional 3,300,000 units at the IPO price to cover over-allotments [1] Group 2 - The Company is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [2] - The management team is led by Gary Quin as CEO and Chairman, and Joseph W. Pooler, Jr. as CFO, with independent directors including Garrett Curran, Alberto Alsina Gonzalez, Dr. Adam Back, and Matthew Murphy [2] Group 3 - Cohen & Company Capital Markets acted as the lead book-running manager for the offering, with Clear Street LLC as joint book-runner [3] - Legal counsel for the Company includes Ellenoff Grossman & Schole LLP and Ogier (Cayman) LLP, while Loeb & Loeb LLP served as legal counsel to the underwriters [3] Group 4 - A registration statement for the units and underlying securities was declared effective by the Securities and Exchange Commission on May 15, 2025 [4]

Core Viewpoint - Antalpha Platform Holding Company has announced the pricing of its initial public offering (IPO) of 3,850,000 ordinary shares at $12.80 per share, with trading expected to begin on Nasdaq under the ticker symbol "ANTA" on May 14, 2025 [1] Group 1: IPO Details - The offering includes a 30-day option for underwriters to purchase an additional 577,500 ordinary shares to cover over-allotments [2] - Antalpha expects to receive gross proceeds of approximately $49.3 million from the offering, which could increase to approximately $56.7 million if the over-allotment option is fully exercised [3] - The offering is set to close on May 15, 2025, subject to customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including investment in product development, sales and marketing, technology infrastructure, capital expenditure, global expansion, and other administrative matters [3] - The company plans to allocate funds for loan operations and customer funding advances to enhance fund flow and customer experience [3] - Antalpha also intends to invest in technologies, solutions, or businesses that complement its operations, as well as in Bitcoin and gold in digital form as part of its treasury management [3] Group 3: Company Background - Antalpha is a leading crypto fintech company focused on providing liquidity and risk management solutions to institutional Bitcoin miners [7] - The company serves as the primary lending partner of Bitmain, offering supply chain and margin loans through its Antalpha Prime technology platform [7]

Core Viewpoint - Apimeds Pharmaceuticals US, Inc. has successfully completed its initial public offering, raising $13.5 million to fund clinical trials and other operational needs [1][3]. Group 1: Initial Public Offering Details - The company closed its initial public offering of 3,375,000 shares at a price of $4.00 per share, with trading commencing on May 9, 2025 [1]. - Gross proceeds from the offering amounted to $13.5 million before expenses [1]. - Underwriters were granted a 45-day option to purchase an additional 506,250 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to fund a Phase III clinical trial for knee osteoarthritis [3]. - The company plans to initiate at least one non-registered corporate sponsorship study in multiple sclerosis [3]. - Proceeds will also be allocated for manufacturing its product candidate and general working capital needs [3]. Group 3: Company Overview - Apimeds is a clinical stage biopharmaceutical company developing Apitox, a bee venom-based toxin with potential therapeutic effects [6]. - The product is being developed as a treatment for knee pain in osteoarthritis patients who do not respond adequately to conventional therapies [6].

Company Overview - Perimeter Acquisition Corp. I is a special purpose acquisition company targeting companies in the defense and national security sectors, leveraging its management's extensive investment and operational experience [5] - The company also aims to explore opportunities at the intersection of defense, technology, and national security, believing its management team can drive value creation post-business combination [5] Initial Public Offering (IPO) Details - The company announced the pricing of its upsized initial public offering of 21,000,000 units at $10.00 per unit, with units expected to trade on Nasdaq under the ticker symbol "PMTRU" starting May 13, 2025 [1] - The offering is anticipated to close on May 14, 2025, subject to customary closing conditions, with Citigroup Global Markets Inc. serving as the sole book-running manager [2] - An additional 3,150,000 units may be purchased by the underwriter to cover over-allotments [2] Regulatory and Compliance Information - A registration statement on Form S-1 related to these securities has been filed with the SEC and was declared effective on May 12, 2025, with the offering being made only by means of a prospectus [3]

Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the pricing of its initial public offering of 3,375,000 shares of common stock at a price of $4.00 per share. The gross proceeds to Apimeds from the offering, b ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Dune Acquisition Corporation II (the “Company”) announced today the closing of its initial public offering of 14,375,000 units, including the exercise in full of the underwriters’ over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $143,750,000. The units are listed on the Nasdaq Global Market (the “Nasdaq”) and commenced trading under the ticker symbol “IPODU” on May 7, 2025. Each unit consists of one Class A ordinary ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Dune Acquisition Corporation II (the “Company”) announced today the pricing of its initial public offering of 12,500,000 units at a price of $10.00 per unit. The units will be listed on The Nasdaq Global Market (the “Nasdaq”) and trade under the ticker symbol “IPODU” beginning on May 7, 2025. Each unit consists of one Class A ordinary share and three-quarters of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a ...

New York, NY, May 02, 2025 (GLOBE NEWSWIRE) -- Republic Digital Acquisition Company (the “Company”) announced today the closing of its initial public offering of 30,000,000 units, which includes 3,600,000 units issued pursuant to the exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $300,000,000. The Company’s units began trading on May 1, 2025 on the Nasdaq Global Stock Market LLC (“Nasdaq”) under the ticker symbol “RDAGU ...